Vertellus has signed a definitive agreement to acquire the potassium chloride, caustic pellets and vaccine adjuvant businesses of diversified US chemical firm Chemtrade. Terms were not disclosed. The transaction is expected to close during Q4, subject to regulatory approval and customary closing conditions.
At its virtual capital markets day on 9 September, Merck KGaA announced that it aims to increase group sales by 6%/year to about €25 billion/year by 2025. To this end, investment, which will increase by 50% in the years 2021-2025 compared to 2016-2020.
“We will continue to consistently and purposefully invest in areas that make us strong,” said CEO and executive board chair Belén Garijo (pictured). Merck will also seek targeted acquisitions, which are most likely to be small to medium-sized.